Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1642 1643 1646
This examiner grants 59% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18579425 | HUMAN IPSC-DERIVED MACROPHAGE | Non-Final OA | The Regents of the University of California |
| 18571833 | ANTIBODIES SPECIFIC TO NELL2 AND METHODS OF USE | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 17704746 | METHODS AND COMPOSITIONS COMPRISING A CD93/IGFBP7 BLOCKING AGENT FOR TREATING CANCER | Final Rejection | The Regents of the University of Colorado, a body corporate |
| 17928778 | COMPOSITION COMPRISING HIF-1 ALPHA ANTIBODY FOR TREATING CANCER | Final Rejection | Arizona Board of Regents on Behalf of the University of Arizona |
| 18277573 | INHIBITORS OF IL-11 OR IL-11Ra FOR USE IN THE TREATMENT OF ABNORMAL UTERINE BLEEDING | Non-Final OA | BAYER AKTIENGESELLSCHAFT |
| 18596320 | METHODS OF INDUCING CARDIAC CELL PROLIFERATION AND INDUCING HEART REGENERATION | Non-Final OA | Wisconsin Alumni Research Foundation |
| 17955743 | Use Of Biomarker Or Biomarkers Combinations In Preparing A Diagnostic Reagent For Fulminant Myocarditis And A Drug For Fulminant Myocarditis | Final Rejection | Wuhan Ktai Biotechnology Company Limited |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy